Cortirio

Cortirio operates at the intersection of medical devices, diagnostics, wearables, and digital health, targeting a problem normally addressed with larger and less accessible imaging infrastructure. Its proposed differentiation is not simply a wearable form factor: the company combines infrared brain imaging, blood-flow mapping, automated detection, and continuous monitoring in a portable system intended for point-of-care use. That focus could make the technology relevant in emergency departments, ambulances, remote settings, and other environments where conventional imaging is slow or unavailable. The company’s disclosed product is a Portable Brain Injury Scanner, with stated applications in traumatic brain injury and stroke. Relative to broader neurotechnology and medical-device companies, Cortirio appears to be an early-stage specialist rather than a scaled commercial manufacturer. Its competitive position will likely depend on clinical validation, diagnostic accuracy, regulatory clearance, workflow integration, and evidence that its approximately two-minute assessment improves decisions compared with existing triage methods.

Cortirio’s trajectory shows a transition from early private backing into grant-supported development of a regulated medical device. The company was founded in 2017, with Patrick Beldon and Paul Macey remaining its CEO and CTO respectively. The next documented inflection point was an Innovate UK grant of $786,520 announced on Dec 1, 2023, followed by a $125,222 National Institute for Health and Care Research grant on Dec 9, 2024. The structured funding total is $911,742 across three rounds, reflecting the two quantified grants and an undisclosed seed round. Cortirio currently falls in the 11–50 employee range, while its active featured team contains three current positions. Hiring commentary indicates that the company is not currently hiring but expects to seek software, electronics, medical-device regulatory, and production talent. This suggests a focus on engineering, compliance, and manufacturing readiness rather than rapid commercial expansion.